FDA Approves Daraxonrasib for Pancreatic Cancer, Nearly Doubling Patient Survival
The FDA approved daraxonrasib for metastatic pancreatic cancer on August 26, the first drug to successfully target KRAS mutations that drive 90 percent of these tumors. In the Phase 3 trial, patients
Follow